The global market for antibody-drug conjugates (ADCs) has seen significant deal activity. According to industry data, since 2020, there have been approximately 300 global M&A and licensing transactions in the ADC space, with a disclosed total value exceeding $215 billion. Chinese innovators contributed about 44% of this value, establishing China as a core hub for global ADC R&D. As a pre-commercial biotech company focused on ADCs and advanced immunotherapies, Mingyu Pharmaceutical has recently submitted a new application to list on the Main Board of the Hong Kong Stock Exchange.

The company was founded in 2018 by Dr. Cao Guoqing, a former senior biologist and research advisor at Eli Lilly and former vice president of Jiangsu Hengrui Pharmaceuticals. It has secured backing from premier biopharmaceutical investment firms, including OrbiMed and Qiming Venture Partners. Following its Series C financing round, the company's valuation reached approximately 3.936 billion yuan. Leveraging a dual-engine strategy of oncology combination therapies and late-stage autoimmune assets, Mingyu Pharmaceutical has managed to recognize revenue in the hundreds of millions of yuan through out-licensing (business development) deals, even before its first product has been commercially launched.

Assessing the Financial and Pipeline Position

However, the financial data and pipeline details disclosed in the prospectus clearly indicate that Mingyu Pharmaceutical is in a critical transition phase from a pure R&D entity towards commercialization. In the absence of any product sales, the high burn rate of R&D spending, heavy reliance on a single licensing partner, and a tight cash flow timeline mean this IPO is not merely a fundraising opportunity but a crucial battle for the company to ensure the smooth progression of its late-stage clinical trials and validate its commercial logic.

Dual Focus on ADC and Autoimmune Therapies

The company's current R&D pipeline comprises 11 self-developed candidate products, with domestic and international late-stage clinical projects forming its core assets. In oncology, Mingyu Pharmaceutical employs a differentiated combination strategy of "ADC + advanced immunotherapy." Its core product, MHB036C, is an ADC candidate targeting TROP-2. Compared to existing market products, the company has optimized MHB036C using its proprietary SuperTopoi technology platform. The market potential is vast, with the global drug market for breast cancer and non-small cell lung cancer projected to reach $99 billion and $115.8 billion, respectively, by 2035.

Currently, MHB036C has completed Phase I trials and is in a Phase II combination study with another key immunotherapy asset, MHB039A (a PD-1/VEGF bispecific antibody), for first-line and later-stage non-small cell lung cancer and breast cancer. Another core product supporting the company's "autoimmune" growth engine is MHB018A, a novel subcutaneous anti-IGF-1R VHH antibody for thyroid eye disease. The global TED treatment market is currently dominated by intravenous infusion products like Tepezza from Amgen Inc, which generated approximately $1.9 billion in sales in 2025.

The company's prospectus notes that intravenous products like Tepezza face convenience limitations due to multiple, lengthy infusions per treatment course and carry risks of infusion-related reactions and adverse events. In contrast, Mingyu Pharmaceutical's MHB018A is administered subcutaneously once every four weeks, reducing the clinical burden on patients.

Beyond these two core products, the company also has MH004, a topical JAK inhibitor for which a New Drug Application for atopic dermatitis in China was submitted in March 2026. This product is expected to gain approval in the first half of 2027 and contribute the company's first sustainable commercial product sales revenue.

Licensing Deals Provide Early Revenue

Despite not having any self-developed products on the market, Mingyu Pharmaceutical has successfully generated non-commercial revenue through out-licensing deals. In March 2025, the company entered into an exclusive licensing agreement with Qilu Pharmaceutical for the development and commercialization of its key product MHB088C in Greater China.

Under the agreement, Mingyu Pharmaceutical granted exclusive rights in the licensed territory to Qilu Pharmaceutical, receiving a non-refundable upfront payment of 280 million yuan, along with potential development, registration, and sales milestone payments of up to 1.065 billion yuan, plus tiered royalties. This deal provided the company's sole revenue for 2025. It is important to note, however, that revenue from such business development models is highly uncertain and episodic. If subsequent clinical events do not meet expectations or if the cooperation agreement is terminated, the company risks losing future milestone payments.

Financial Pressures and High R&D Burn

The disclosed financial data of Mingyu Pharmaceutical exhibits typical characteristics of a pre-commercial biotech company: high R&D investment, no sustained commercial sales revenue, and heavy reliance on a single licensed project. In terms of revenue, the company recorded zero operating income in 2024. In 2025, recognizing the upfront and milestone payments from the Qilu Pharmaceutical agreement, it achieved operating income of 264 million yuan, with a gross profit of 264 million yuan and a gross margin of 99.7%. However, for the five months ended May 31, 2026, operating income plummeted back to zero.

Regarding R&D expenses, the company spent 281 million yuan and 230 million yuan in 2024 and 2025, respectively. In the first five months of 2026, R&D expenses surged to 120 million yuan from 60.06 million yuan in the same period of 2025, doubling year-on-year. This sharp increase is primarily due to the full initiation of multiple late-stage clinical trials, including the Phase III registration trial for the core product MHB018A in China for active and chronic TED, and the Phase II combination study for MHB036C and MHB039A. Outsourced preclinical and clinical costs dominated the total R&D expenditure, reaching 99.7 million yuan in the first five months of 2026.

Concurrently, as the company's structure expanded and IPO preparations progressed, its administrative expenses grew from 13.54 million yuan in 2024 to 37.05 million yuan in 2025, reaching 14.83 million yuan in the first five months of 2026.

Persistent Losses and Tight Cash Flow

In terms of profitability, Mingyu Pharmaceutical has been in a continuous loss-making state since its inception. The net loss was 283 million yuan in 2024. In 2025, despite recognizing 264 million yuan in licensing revenue, the company recorded a massive fair value loss of 928 million yuan related to convertible preferred shares issued in prior equity financing rounds. This led to a sharp increase in the annual loss attributable to owners to 919 million yuan.

While this nearly 1-billion-yuan fair value loss is a non-cash, non-operating accounting item and will be eliminated upon the automatic conversion of these preferred shares to ordinary shares post-successful listing, the company's actual operating losses remain high even after excluding this non-recurring item.

Against this backdrop of high outflows and minimal inflows, Mingyu Pharmaceutical's cash flow situation and runway are particularly pressing. In terms of operating cash flow, apart from a net inflow of 154 million yuan in the first five months of 2025 due to receiving the upfront payment from Qilu Pharmaceutical, the company recorded net cash outflows from operating activities of 146 million yuan, 183 million yuan, and 181 million yuan in 2024, 2025, and the first five months of 2026, respectively.

As of May 31, 2026, the company's cash and cash equivalents balance stood at 605 million yuan, primarily from the $131 million Series C financing completed in July 2025. Extrapolating the cash burn rate of 181 million yuan from the first five months of 2026, the existing funds could sustain operations for approximately 16 to 18 months without considering any new external financing or milestone payments. This严峻的资金红线 underscores the urgency of Mingyu Pharmaceutical's Hong Kong IPO.

Key Risks and Challenges Ahead

Beyond cash burn pressure, the company's potential risks are not solely financial. First, it faces high "single-partner dependency risk." If Qilu Pharmaceutical encounters setbacks in the subsequent clinical development of MHB088C, or if disputes arise, Mingyu Pharmaceutical's financial outlook would be severely impacted. Second, the company has no manufacturing facilities and relies entirely on third-party CDMOs for production. In an increasingly complex geopolitical environment, changes in external regulatory policies could pose potential threats to the stability of its CDMO supply chain.

Furthermore, the TROP-2 ADC and TED treatment fields are highly competitive. In an environment where the Hong Kong stock market is applying more rational valuations to biopharmaceutical assets, whether Mingyu Pharmaceutical can successfully replenish its arsenal through the IPO and achieve the smooth approval and sales launch of its first product, MH004, within its cash runway will determine if it can break through in this long, high-R&D, high-burn race of innovative drug development.

In summary, with its布局 in oncology combination therapies and late-stage autoimmune assets, Mingyu Pharmaceutical has demonstrated corresponding technological value and business development foresight in its pre-commercial stage. However, hard indicators such as extreme reliance on a single project, surging R&D expenses, and tight cash flow also reflect the systemic survival challenges普遍 faced by pre-commercial pharmaceutical companies. The future for Mingyu Pharmaceutical will be an极限拉力赛 between the speed of technological breakthroughs and the pace of cash consumption.